SemOpenAlex |

SemOpenAlex

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321606338> ?p ?o ?g. }

Showing items 1 to 100 of ±245 with 100 items per page.

W4321606338 endingPage "562" @default.
W4321606338 startingPage "550" @default.
W4321606338 abstract "Elexacaftor-tezacaftor-ivacaftor has been shown to be safe and efficacious in people with cystic fibrosis and at least one F508del allele. Our aim was to identify a novel cystic fibrosis transmembrane conductance regulator (CFTR) modulator combination capable of further increasing CFTR-mediated chloride transport, with the potential for once-daily dosing.We conducted two phase 2 clinical trials to assess the safety and efficacy of a once-daily combination of vanzacaftor-tezacaftor-deutivacaftor in participants with cystic fibrosis who were aged 18 years or older. A phase 2 randomised, double-blind, active-controlled study (VX18-561-101; April 17, 2019, to Aug 20, 2020) was carried out to compare deutivacaftor monotherapy with ivacaftor monotherapy in participants with CFTR gating mutations, following a 4-week ivacaftor monotherapy run-in period. Participants were randomly assigned to receive either ivacaftor 150 mg every 12 h, deutivacaftor 25 mg once daily, deutivacaftor 50 mg once daily, deutivacaftor 150 mg once daily, or deutivacaftor 250 mg once daily in a 1:1:2:2:2 ratio. The primary endpoint was absolute change in ppFEV1 from baseline at week 12. A phase 2 randomised, double-blind, controlled, proof-of-concept study of vanzacaftor-tezacaftor-deutivacaftor (VX18-121-101; April 30, 2019, to Dec 10, 2019) was conducted in participants with cystic fibrosis and heterozygous for F508del and a minimal function mutation (F/MF genotypes) or homozygous for F508del (F/F genotype). Participants with F/MF genotypes were randomly assigned 1:2:2:1 to receive either 5 mg, 10 mg, or 20 mg of vanzacaftor in combination with tezacaftor-deutivacaftor or a triple placebo for 4 weeks, and participants with the F/F genotype were randomly assigned 2:1 to receive either vanzacaftor (20 mg)-tezacaftor-deutivacaftor or tezacaftor-ivacaftor active control for 4 weeks, following a 4-week tezacaftor-ivacaftor run-in period. Primary endpoints for part 1 and part 2 were safety and tolerability and absolute change in ppFEV1 from baseline to day 29. Secondary efficacy endpoints were absolute change from baseline at day 29 in sweat chloride concentrations and Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory domain score. These clinical trials are registered with ClinicalTrials.gov, NCT03911713 and NCT03912233, and are complete.In study VX18-561-101, participants treated with deutivacaftor 150 mg once daily (n=23) or deutivacaftor 250 mg once daily (n=24) had mean absolute changes in ppFEV1 of 3·1 percentage points (95% CI -0·8 to 7·0) and 2·7 percentage points (-1·0 to 6·5) from baseline at week 12, respectively, versus -0·8 percentage points (-6·2 to 4·7) with ivacaftor 150 mg every 12 h (n=11); the deutivacaftor safety profile was consistent with the established safety profile of ivacaftor 150 mg every 12 h. In study VX18-121-101, participants with F/MF genotypes treated with vanzacaftor (5 mg)-tezacaftor-deutivacaftor (n=9), vanzacaftor (10 mg)-tezacaftor-deutivacaftor (n=19), vanzacaftor (20 mg)-tezacaftor-deutivacaftor (n=20), and placebo (n=10) had mean changes relative to baseline at day 29 in ppFEV1 of 4·6 percentage points (-1·3 to 10·6), 14·2 percentage points (10·0 to 18·4), 9·8 percentage points (5·7 to 13·8), and 1·9 percentage points (-4·1 to 8·0), respectively, in sweat chloride concentration of -42·8 mmol/L (-51·7 to -34·0), -45·8 mmol/L (95% CI -51·9 to -39·7), -49·5 mmol/L (-55·9 to -43·1), and 2·3 mmol/L (-7·0 to 11·6), respectively, and in CFQ-R respiratory domain score of 17·6 points (3·5 to 31·6), 21·2 points (11·9 to 30·6), 29·8 points (21·0 to 38·7), and 3·3 points (-10·1 to 16·6), respectively. Participants with the F/F genotype treated with vanzacaftor (20 mg)-tezacaftor-deutivacaftor (n=18) and tezacaftor-ivacaftor (n=10) had mean changes relative to baseline (taking tezacaftor-ivacaftor) at day 29 in ppFEV1 of 15·9 percentage points (11·3 to 20·6) and -0·1 percentage points (-6·4 to 6·1), respectively, in sweat chloride concentration of -45·5 mmol/L (-49·7 to -41·3) and -2·6 mmol/L (-8·2 to 3·1), respectively, and in CFQ-R respiratory domain score of 19·4 points (95% CI 10·5 to 28·3) and -5·0 points (-16·9 to 7·0), respectively. The most common adverse events overall were cough, increased sputum, and headache. One participant in the vanzacaftor-tezacaftor-deutivacaftor group had a serious adverse event of infective pulmonary exacerbation and another participant had a serious rash event that led to treatment discontinuation. For most participants, adverse events were mild or moderate in severity.Once-daily dosing with vanzacaftor-tezacaftor-deutivacaftor was safe and well tolerated and improved lung function, respiratory symptoms, and CFTR function. These results support the continued investigation of vanzacaftor-tezacaftor-deutivacaftor in phase 3 clinical trials compared with elexacaftor-tezacaftor-ivacaftor.Vertex Pharmaceuticals." @default.
W4321606338 created "2023-02-24" @default.
W4321606338 creator A5000385368 @default.
W4321606338 creator A5001014693 @default.
W4321606338 creator A5002301240 @default.
W4321606338 creator A5002960800 @default.
W4321606338 creator A5003614183 @default.
W4321606338 creator A5003812454 @default.
W4321606338 creator A5003887415 @default.
W4321606338 creator A5005146182 @default.
W4321606338 creator A5008375832 @default.
W4321606338 creator A5008856093 @default.
W4321606338 creator A5010924080 @default.
W4321606338 creator A5010952511 @default.
W4321606338 creator A5011103630 @default.
W4321606338 creator A5011360899 @default.
W4321606338 creator A5011506804 @default.
W4321606338 creator A5012232604 @default.
W4321606338 creator A5012298165 @default.
W4321606338 creator A5012496988 @default.
W4321606338 creator A5014211264 @default.
W4321606338 creator A5018336278 @default.
W4321606338 creator A5018629804 @default.
W4321606338 creator A5018938489 @default.
W4321606338 creator A5019319489 @default.
W4321606338 creator A5019729863 @default.
W4321606338 creator A5019952468 @default.
W4321606338 creator A5026662162 @default.
W4321606338 creator A5027118818 @default.
W4321606338 creator A5029091133 @default.
W4321606338 creator A5031205333 @default.
W4321606338 creator A5031617022 @default.
W4321606338 creator A5031909028 @default.
W4321606338 creator A5032049589 @default.
W4321606338 creator A5032651431 @default.
W4321606338 creator A5037413141 @default.
W4321606338 creator A5038720927 @default.
W4321606338 creator A5039744000 @default.
W4321606338 creator A5040330750 @default.
W4321606338 creator A5040461519 @default.
W4321606338 creator A5040631103 @default.
W4321606338 creator A5040666131 @default.
W4321606338 creator A5041527005 @default.
W4321606338 creator A5041794497 @default.
W4321606338 creator A5044489402 @default.
W4321606338 creator A5044888615 @default.
W4321606338 creator A5048583603 @default.
W4321606338 creator A5050739505 @default.
W4321606338 creator A5052909330 @default.
W4321606338 creator A5053035402 @default.
W4321606338 creator A5053308496 @default.
W4321606338 creator A5054239026 @default.
W4321606338 creator A5059010278 @default.
W4321606338 creator A5059712547 @default.
W4321606338 creator A5060857023 @default.
W4321606338 creator A5060910016 @default.
W4321606338 creator A5065521966 @default.
W4321606338 creator A5066576161 @default.
W4321606338 creator A5067563759 @default.
W4321606338 creator A5068153788 @default.
W4321606338 creator A5068675129 @default.
W4321606338 creator A5068917441 @default.
W4321606338 creator A5068929859 @default.
W4321606338 creator A5070928330 @default.
W4321606338 creator A5071899876 @default.
W4321606338 creator A5072577936 @default.
W4321606338 creator A5073156530 @default.
W4321606338 creator A5073764412 @default.
W4321606338 creator A5075092345 @default.
W4321606338 creator A5075155319 @default.
W4321606338 creator A5075205722 @default.
W4321606338 creator A5077729911 @default.
W4321606338 creator A5078412807 @default.
W4321606338 creator A5078925906 @default.
W4321606338 creator A5080682322 @default.
W4321606338 creator A5081109279 @default.
W4321606338 creator A5081337553 @default.
W4321606338 creator A5081612944 @default.
W4321606338 creator A5082181496 @default.
W4321606338 creator A5082871985 @default.
W4321606338 creator A5083949791 @default.
W4321606338 creator A5084138436 @default.
W4321606338 creator A5085088557 @default.
W4321606338 creator A5085349706 @default.
W4321606338 creator A5086628162 @default.
W4321606338 creator A5086716042 @default.
W4321606338 creator A5088249472 @default.
W4321606338 creator A5090241740 @default.
W4321606338 creator A5091845418 @default.
W4321606338 date "2023-06-01" @default.
W4321606338 modified "2023-10-16" @default.
W4321606338 title "Safety and efficacy of vanzacaftor–tezacaftor–deutivacaftor in adults with cystic fibrosis: randomised, double-blind, controlled, phase 2 trials" @default.
W4321606338 cites W2035131077 @default.
W4321606338 cites W2071407356 @default.
W4321606338 cites W2144788850 @default.
W4321606338 cites W2155421119 @default.
W4321606338 cites W2416119256 @default.
W4321606338 cites W2533625518 @default.